Introduction: Combination inhaled corticosteroid/long-acting bronchodilator (ICS/LABA) therapy reduces the exacerbation rate and improves spirometry and quality of life in COPD. We hypothesized that ICS/LABA therapy also improves small airway function measured by FOT. Methods: 14 subjects with COPD were commenced on combination fluticasone propionate/salmeterol therapy for 3 months. At baseline, subjects completed the St George Respiratory Questionnaire (SGRQ) and underwent standard pulmonary function tests as well as forced oscillation technique (FOT) and single and multiple breath nitrogen washouts. All tests were repeated at the completion of 3 months of therapy. (À1.21 cmH 2 O/L/s, p Z 0.02) also improved. There were no significant changes in ventilation heterogeneity indices. Conclusion: Combination therapy is associated with improvements in small airways function in COPD, despite an absence of change in FEV 1 . FOT may be a clinically useful marker of small airway function in COPD that is responsive to treatment. ª
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Summary Introduction: Combination inhaled corticosteroid/long-acting bronchodilator (ICS/LABA) therapy reduces the exacerbation rate and improves spirometry and quality of life in COPD. We hypothesized that ICS/LABA therapy also improves small airway function measured by FOT. Methods: 14 subjects with COPD were commenced on combination fluticasone propionate/salmeterol therapy for 3 months. At baseline, subjects completed the St George Respiratory Questionnaire (SGRQ) and underwent standard pulmonary function tests as well as forced oscillation technique (FOT) and single and multiple breath nitrogen washouts. All tests were repeated at the completion of 3 months of therapy. Results: Subjects were of mean (SD) age 65.9 years (8.4), BMI 30.0 (5.6), pack years 51.4 (21.1), post-bronchodilator FEV 1 % predicted 62.7 (20) . At baseline, mean SGRQ total was 39.0 (17.7) and FRC% predicted 125. 4 (31.3) . From FOT, Rrs-total was 5.69 (1.29) cmH 2 O/L/ s, Xrs-total À3.48 (2.16) cmH 2 O/L/s, EFL Index 3.51 (2.45) cmH 2 O/L/s. After 3 months of therapy, there were significant improvements in SGRQ score (À13.81, p < 0.0001) despite no change in FEV 1 ( þ40 mL, p Z 0.14). From FOT, total resistance ( À0.63 cmH 2 O/L/s, p Z 0.0004), reactance (þ1.2 cmH 2 O/L/s, p Z 0.013), and expiratory flow limitation
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is associated with significant morbidity, mortality, and economic burden. International guidelines recommend prescription of long-acting bronchodilators (long-acting beta-agonists (LABA) or muscarinic antagonists (LAMA)) for symptomatic COPD patients with moderate airflow obstruction [1] , while inhaled corticosteroids (ICS) are recommended when the FEV 1 is less than 50% of predicted and acute exacerbations are present [1] . ICS/LABA combination treatment improves symptoms, quality of life, and exacerbation rate [2e4] as well as physiological measures such as spirometry, inspiratory capacity (IC) and dynamic hyperinflation [5, 6] . Treatment responses in terms of more detailed physiological measures such as airway resistance and nitrogen washout have not been assessed. These are advantageous and may add complementary information since they generally represent lung function during normal tidal breathing.
Forced oscillation technique (FOT) is an effortindependent method for measuring lung mechanics. The FOT parameters of resistance (Rrs) and reactance (Xrs) are indices of airway calibre and of the elastic properties of the respiratory system, respectively, and reflect both small and large airway properties. Xrs is sensitive and specific to the presence of expiratory flow limitation (EFL) in COPD [7] and to change during recovery from acute exacerbations of COPD [8] . Rrs and Xrs are also sensitive to changes following bronchodilator inhalation in COPD [9, 10] . Although Rrs and Xrs improve in asthmatic subjects following ICS and ICS/LABA combination therapy [11, 12] , there are no comparable studies in COPD.
The nitrogen washout tests provide indices of airway closure and heterogeneity in ventilation distribution. A single breath nitrogen washout (SBNW) measures closing volume (CV) and the phase III slope, which correlate with small airway pathology in smokers [13] . There is evidence that CV reflects small airway dysfunction in COPD that is due to inflammation and remodelling, separately from the effects of reduced parenchymal support due to emphysema [14] The multiple breath nitrogen washout (MBNW) allows partitioning of ventilation distribution into the convection dependent airways (Scond) and convection-diffusion dependent airways (Sacin) [15] . The MBNW parameters are sensitive to early small airways disease in smokers [16] but do not change in response to bronchodilator administration in severe COPD [17] .
In this study, we aimed to determine and interpret changes in small airway function measured by FOT during ICS/LABA treatment in COPD over a 3-month period. We measured changes in Rrs, Xrs and EFL derived from FOT; in closing capacity (CC) and phase III slope from SBNW; and in Scond and Sacin from MBNW. We hypothesized that significant improvements in FOT variables would occur following the commencement of therapy in the absence of significant change in spirometry or ventilation heterogeneity. 
Abbreviations
Methods
Subject characteristics
Subjects were recruited from a volunteer database at Royal North Shore Hospital and advertisements in a local newspaper. Inclusion criteria were age 40 years or older, a physician diagnosis of COPD, smoking history of greater than 10 pack years, post-bronchodilator FEV 1 /FVC <0.7, no regular inhaled steroid use in the past 3 months and symptoms of shortness of breath on exertion or chronic cough for at least 12 months. Subjects were excluded if they had a coexistent diagnosis of asthma or other respiratory disease, or an exacerbation of COPD within the last 6 weeks defined as an increase in COPD symptoms for 3 or more days that necessitated an increase in treatment. Written informed consent was obtained from each subject prior to enrolment. The experimental protocol was approved by the Hawkesbury/Harbour Human Research Ethics Committee of Northern Sydney Central Coast Health (0903-050M).
Study design
This was a longitudinal, open label, observation study of inhaled fluticasone/salmeterol treatment in COPD over 3 months. Combination fluticasone/salmeterol 250/25 mg (Seretide Metered Dose Inhaler, GlaxoSmithKline) 2 puffs twice daily through an E-Chamber 500 mL Spacer (Bird Healthcare) was commenced the next day after their first visit. Subjects attended a total of 4 visits; at the start of the study and every month for 3 months. The dose counters of the fluticasone/salmeterol inhalers were noted at each visit to provide an indication of adherence. Subjects did not withhold their usual COPD medication prior to all testing.
At the first visit, subjects completed a questionnaire about respiratory symptoms, medication use, and smoking history. Health related quality of life was assessed using the St George's Respiratory Questionnaire (SGRQ) with a 3-month recall period [18] . Baseline dyspnoea index (BDI) was also calculated [19] . Lung function tests were performed in the following order: FOT, spirometry, diffusing capacity, SBNW, MBNW, and lung volume measurements by body plethysmography. Subjects then performed postbronchodilator spirometry 15 min after 400 mcg of inhaled salbutamol. Subjects completed FOT and spirometry only at the 1-and 2-month visits. At the end of 3 months' of treatment, subjects repeated the baseline tests in the same order. SGRQ was again completed, and change in dyspnoea was assessed by the transitional dyspnoea index (TDI) [19] .
Forced oscillation technique (FOT)
Respiratory system resistance (Rrs) and reactance (Xrs) were measured at an oscillation frequency of 6 Hz. The FOT device was developed in house [20] and conforms to the general design and specifications for FOT machines [21] . Oscillations were generated by a loudspeaker with flow and pressure measured at the airway opening by a screen pneumotachograph and solid-state pressure transducer. Three separate measurements were made during tidal breathing for 60 s. Data were processed using a complete breath method where breaths with extreme and negative Rrs values or artifacts were excluded from any subsequent processing [22] . After processing, the mean Rrs or Xrs value within the whole breath (Rrs-total and Xrs-total) as well as those corresponding to the inspiratory component only (Rrs-insp and Xrs-insp) were calculated over all included breaths. The Rrs-insp and Xrsinsp are theoretically measurements of respiratory mechanics that are unaffected by the presence of expiratory flow limitation [7] . Predicted values for Rrs and Xrs were those of Brown et al. [23] .
To assess expiratory flow limitation, the EFL Index was calculated as the mean difference between the mean inspiratory (Xrs-insp) and expiratory (Xrs-exp) reactance values of each breath [7] . Although a threshold value of >2.8 cmH 2 O/L/s was shown to indicate the presence of expiratory flow limitation in COPD, the index was treated as a continuous variable in data analyses.
Spirometry, body plethysmography, and diffusing capacity
Spirometry and diffusing capacity were performed according to American Thoracic Society/European Respiratory Society using a Medgraphics system (MedGraphics Ultima Series, Medical Graphics Corporation Minnesota USA) [24, 25] . Lung volumes were measured by body plethysmography using a Sensormedics Vmax BodyBox (Sensormedics Corporation, Yorba Linda, CA, USA). Results are reported as absolute and percent of predicted values [26e28].
Single breath nitrogen washout (SBNW)
Closing volume (CV) and slope of phase III were measured using the same Medgraphics system. Pure oxygen was inhaled at a flow rate <50 L/min from residual volume (RV) to total lung capacity (TLC), followed by exhalation at a flow rate of 30 L/min from TLC to RV. A plot of exhaled N 2 concentration versus lung volume was used to calculate the alveolar slope (slope of phase III) and closing volume, CV. Closing capacity (sum of CV and plethysmographic RV) was calculated as a fraction of plethysmographic total lung capacity (CC/TLC).
Multiple breath nitrogen washout (MBNW)
Ventilation heterogeneity was measured by the multiple breath nitrogen washout as previously described [29] . Briefly, a closed-circuit, bag-in-box breathing system was used to deliver 100% oxygen, which subjects breathed at a tidal volume of 1.0e1.3 L, at a respiratory frequency of 9e12 breaths/min, until end-tidal nitrogen concentration was 1/40th of the starting alveolar nitrogen concentration. The indices of ventilation heterogeneity determined predominantly by convection dependent (Scond) and by diffusion-convection dependent (Sacin) mechanisms were derived as previously described [15] .
Statistical analysis
Statistical analyses was performed using Analyse-it Ò for Excel Ò (Analyse-It Software Ltd, Leeds, England) and IBM(R) SPSS(R) Statistics version 20.0 (Armonk, NY, USA). Data are presented as means with standard deviations (SD) unless otherwise specified. p Values of <0.05 were considered statistically significant. ShapiroeWilk test was used to assess normality of data variables.
Changes in small airways function Changes in FOT variables from baseline over 3 months treatment were examined using a 1-way repeated measures analysis of variance (ANOVA). Dunnett's posthoc test was used to assess pairwise differences between individual visits.
Changes in spirometry, FRC, MBNW variables, SBNW variables, and SGRQ from baseline to 3 months were compared using paired t test for parametric variables and Wilcoxon test for nonparametric variables.
Results
14 COPD subjects completed 12 weeks of combination therapy. The baseline demographic characteristics and lung function data of the study subjects are provided in Table 1 . Overall, the subjects had moderate airflow obstruction, a mild increase in resistance, and severely abnormal reactance values. Seven of the 14 subjects had an EFL Index >2.8 cmH 2 O/L/s, a previously used cut-off for presence of expiratory flow limitation [7] . 6 subjects were hyperinflated at baseline, as assessed by FRC. 8 subjects were on no medication, while 6 subjects were taking LAMA therapy. 12 subjects were ICS naïve, while 2 had tried ICS more than 1 year ago. The impairment of quality of life, measured by SGRQ, across the group was fairly mild, although there was a broad range of impact (9.83e74.49). At baseline, SGRQ total score correlated with Scond (r-0.62, p0.02) and SGRQ impact score correlated with Scond (r-0.61, p0.02) and Sacin (r s 0.53, p 0.05). Table 2 contains the baseline and end of study measurements of small airways function. Significant improvements were seen in all FOT parameters: Rrs-total, Xrs-total, EFL Index, Rrs-insp, and Xrs-insp. No significant changes in ventilation heterogeneity or closure were identified. Likewise, no significant change in the spirometric parameters was seen. From the ANOVA, no significant differences were seen for Rrs-total (p Z 0.332) and Rrs-insp (p Z 0.51). Significant differences between the 4 study visits were seen for Xrs-insp (p Z 0.025), Xrs-total (p Z 0.003), and EFL Index (p Z 0.002).
Small airway measurements
The mean FOT parameters at each of the 4 study visits are displayed in Fig. 1(a) e(e). No significant differences could be seen at any of the study visits in comparison to visit 1 for Rrs-total or Rrs-insp. In comparison to visit 1, significant changes could be seen in Xrs-total at visit 2 (p Z 0.02), visit 3 (p Z 0.06), and visit 4 (p Z 0.09). Significant differences in Xrs-insp compared to visit 1 could be seen at visit 2 (p Z 0.015) and visit 4 (p Z 0.032) but not visit 3 (p Z 0.232). In comparison to visit 1, significant differences in EFL Index could be seen at each study visit: visit 2 (p Z 0.002), visit 3 (p Z 0.002), visit 4 (p Z 0.014).
Quality of life, dyspnoea, and hyperinflation
Quality of life assessed by SGRQ (n Z 13) improved significantly from 39.85 (18.16 ) at baseline to 27.22 (13.67) at the completion of the study (mean difference 12.63 (7.91), p < 0.0001). There was a significant change in dyspnoea as 
Discussion
Summary of findings
This small proof of concept study showed that parameters of small airways function measured by FOT were sensitive to modest change with therapy in COPD, in contrast to ventilation heterogeneity, closure and spirometry. All FOT parameters showed significant change with combination ICS/LABA therapy. Significant changes in quality of life and dyspnoea score also occurred after 3 months of ICS/LABA therapy.
Comparison with other studies
While several studies have examined acute response to bronchodilator with FOT parameters [9, 30] , there are no published studies examining changes in oscillatory impedance in response to therapy in COPD over months. In asthmatics however, there are two published studies that have confirmed the sensitivity of impedance measured by impulse oscillometry to detect changes in small airways mechanics in response to therapy [11, 12] . Serial MBNW measures of ventilation heterogeneity after the introduction of tiotropium in COPD subjects demonstrated that subjects with hyperinflation had a significant increase in pre-dose FEV 1 and inspiratory capacity in the absence of changes in ventilation heterogeneity [17] . Although we used an alternative bronchodilator, a long-acting betaagonist, we also found that bronchodilation did not change ventilation heterogeneity parameters. In comparison to large randomized control trials of combination therapy in COPD [2] , the change in SGRQ quality of life seen in this study was greater than expected, however it is in keeping with results from other small mechanistic studies [31] . The reason for the large improvement in quality of life in our group is likely to be multi-factorial but contributing factors would include the education they received as part of the study regarding COPD and their lung function, the social nature of the study visits, as well as any treatment effects from the ICS/LABA therapy. By the nature of study design and recruitment of steroid naïve patients, most subjects knew very little about the nature of their disease prior to study commencement and had the opportunity to ask questions of the study investigator during the visits. 
Possible mechanisms for improvement in FOT with therapy
LABA gives rise to smooth muscle relaxation even in the presence of normal or increased muscle tone, which results in an increase in airway diameter and improved airflow{Rossi, 2008 #38}. Both LABA and LAMA therapy improve expiratory capacity by shortening the time constants for lung emptying, with a resultant reduction in end-expiratory lung volume (EELV) and increase in inspiratory capacity (IC) [32e34]. These changes lead to improvements in exertional dyspnoea and exercise capacity [33] . Inhaled corticosteroid therapy reduces airway inflammation, which may in turn improve airflow by reducing airway wall thickness [35] . Therefore, one might expect ICS/LABA to reduce Rrs (improve airway calibre) and improve Xrs and EFL (reduced expiratory flow limitation).
Lack of improvement with washout indices
Heterogeneity and closure were not affected by ICS/LABA therapy in this small group. FOT at 6 Hz reflects the contribution of both large and small airways [21] , so the improvements in the FOT parameters may be reflecting improvement in larger airway calibre. In comparison, ventilation heterogeneity and closure are more closely related to peripheral airway function [13, 15] . Given the particle size of ICS/LABA therapy, it is likely that any changes in airway calibre detected by FOT occurred predominantly in the larger airways resulting in fairly homogenous improvements in airflow, with little effect on peripheral airway closure or ventilation heterogeneity. EFL is very sensitive to closure so improvement in closure measured by SBNW would be expected. CC/TLC% improved, however this change was not statistically significant (p 0.28). Improvement in CC alone was 0.21 L (p 0.055).
Strengths and limitations of the study
As we needed to recruit COPD subjects not already taking inhaled corticosteroids, the group overall had moderate airflow obstruction, GOLD stage II. International guidelines would not recommend inhaled corticosteroids in general for moderate airflow obstruction in the absence of exacerbations [1] . Despite the small sample size, we were able to detect changes in FOT where this was not possible with the other measures. High doses of inhaled corticosteroid were used in keeping with the TORCH study [2] . We do not know if lower doses of inhaled corticosteroid or in fact single agent therapy, with either inhaled steroid or LABA, would produce a similar effect. Our subjects were compliant and had complete study attendance, enabling us to collect detailed physiological information about small airway function, and the effects of a commonly prescribed medication on these measures. This is the first study to examine the effects of therapy on small airway mechanics, ventilation heterogeneity, and airway closure.
Conclusions
In this small proof of concept study we have shown that FOT is sensitive to modest change in small airway mechanics with ICS/LABA combination therapy that are not detectable with the standard outcome measure of clinical trials, FEV 1 . Xrs-total, Xrs-insp, and EFL Index improved significantly with ICS/LABA treatment. Measures of the very peripheral small airway function, closure and ventilation heterogeneity, were not effected by ICS/LABA treatment. FOT has been used to monitor recovery from acute exacerbations [8, 36] and is being evaluated as a home monitoring tool in COPD [14, 37] . The results of our study confirm another potential use as a treatment monitoring tool, and lends support to the incorporation of FOT into a randomized control trial of therapy in COPD to confirm the changes we have observed.
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